Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 3,437 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Wednesday, August 2nd, Jeffrey Chodakewitz sold 1,796 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $154.13, for a total transaction of $276,817.48.
  • On Thursday, August 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $154.17, for a total transaction of $830,976.30.
  • On Friday, July 21st, Jeffrey Chodakewitz sold 46,733 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $160.96, for a total transaction of $7,522,143.68.
  • On Monday, July 17th, Jeffrey Chodakewitz sold 573 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $129.85, for a total transaction of $74,404.05.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 152.30 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85. The firm has a market capitalization of $38.40 billion, a P/E ratio of 146.30 and a beta of 1.73. The firm’s 50-day moving average is $153.77 and its 200-day moving average is $133.08.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.33. The business had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Jeffrey Chodakewitz Sells 3,437 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/jeffrey-chodakewitz-sells-3437-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock/1611966.html.

Several research firms have issued reports on VRTX. DA Davidson began coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 price target on the stock. BTIG Research began coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 price target on the stock. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price target on the stock in a research report on Tuesday, September 26th. Finally, Vetr lowered shares of Vertex Pharmaceuticals to a “sell” rating in a research report on Thursday, September 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $167.04.

A number of hedge funds have recently bought and sold shares of VRTX. Baird Financial Group Inc. purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $231,000. Martingale Asset Management L P purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $1,040,000. Nordea Investment Management AB grew its holdings in Vertex Pharmaceuticals by 22.0% during the 1st quarter. Nordea Investment Management AB now owns 12,308 shares of the pharmaceutical company’s stock valued at $1,346,000 after buying an additional 2,223 shares in the last quarter. Schroder Investment Management Group purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $3,317,000. Finally, Neuberger Berman Group LLC grew its holdings in Vertex Pharmaceuticals by 5.1% during the 1st quarter. Neuberger Berman Group LLC now owns 246,331 shares of the pharmaceutical company’s stock valued at $26,936,000 after buying an additional 12,060 shares in the last quarter. 92.85% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.